Find and Pitch Jounalists, Get Your Story Covered

Tags: biotech biotechnology Cancer drug development Drug prices

	Profile	Recent Articles on Subject
1	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	The biotech news stories we’re keeping an eye on - 5 days ago Eli Lilly seeks to join lawsuit on compounded drugs - 16 days ago Merck is a new year outlier with its diabetes drug - 19 days ago The biotech news you need to read today - about 2 months ago Element Biosciences raises another massive round - 6 months ago STAT+: More tumult at BIO amid the company’s fourth CEO in four years - 8 months ago How resurrecting extinct species might impact medicine - 10 months ago Lawmakers want to add more Chinese biotechs to defense list - 10 months ago The biotech updates you need to read today - about 1 year ago The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive - about 1 year ago Novartis is building a new radioligand plant in China - about 1 year ago A new algorithm unveils CRISPR ‘treasure trove’ - about 1 year ago These are the need-to-know biotech stories from this weekend - about 1 year ago Shrinking Covid vaccine sales has Moderna course-correcting - about 1 year ago
2	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	East Asians under-represented in biopharma leadership - 14 days ago A key decision on compounding is expected this week - about 1 month ago Gameto says first baby born using new stem-cell tech - about 1 month ago STAT+: In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu - 8 months ago
3	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	4 companies to watch in the accelerating gene editing race - 20 days ago Who’s winning in biotech’s tight market? - 4 months ago Pharma’s ‘it’ therapy — a new drug class gaining steam - 5 months ago PharmaVoice 100s: Entrepreneurs - about 1 year ago
4	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	A biotech’s race to tackle the most severe hepatitis - about 1 month ago Milk-based therapies could be coming. This biotech CEO is aiming to lead the way. - about 2 months ago Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope. - 5 months ago 4 offbeat biotechs making a splash in the life sciences - 9 months ago These biotech hotspots are ripe for IPOs - 10 months ago
5	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	AI Biotech BenevolentAI Restructures Again, This Time to Return to Its TechBio Roots - about 1 month ago Flagship Pioneering Launches Startup Abiologics to Advance New Class of Biologic Drugs - 6 months ago
6	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Biotech companies detail emerging efforts to ease ‘conditioning’ before genetic treatments - about 1 month ago A biotech’s binary bet ends badly - 7 months ago
7	Sarah Owermohle STAT News Health reporter @STATNews. Covers Biden's agenda. Washington, District of Columbia health policyjournalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 2 months ago
8	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 2 months ago
9	John Wilkerson STAT News STAT Washington correspondent. Healthcare Journalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 2 months ago
10	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	STAT+: Genentech, a biotech with a storied past, confronts new turbulence in the present - 4 months ago STAT+: With biotech in a slump, the industry’s job market is upside down - about 1 year ago STAT+: Failed biotech gives a rare peek inside the tough breaks — and tough choices — that led to its demise - over 1 year ago

Journalists covering biotech